Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 58

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 58
---
 We will retain broad discretion over the use of the net proceeds of this
offering which may result in an allocation of net proceeds in differing amounts than those listed above, or in entirely new areas. The
amount and timing of these proposed expenditures will depend on a number of factors, including the progress product development programs,
and any unforeseen cash needs. As a result, you will be relying on the judgment of our management with regard to the use of these net
proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.
It is possible that the proceeds will be used in a way that does not yield a favorable, or any, return for us. Pending application of
the net proceeds as described above, we intend to invest the proceeds in investment grade interest bearing instruments or will hold the
proceeds in interest bearing or non-interest-bearing bank accounts.

<div align='center'>31

DETERMINATION OF THE OFFERING PRICE</div>

The offering price of the Units in the Primary
Offering has been determined arbitrarily by us. This price does not bear any relationship to our book value, earnings, or other established
criteria that would be evaluated for a company with an established public market. In determining the number of Units to be offered and
the offering price per unit, we took into consideration our cash on hand and the amount of money we would need to implement our business
plan. Accordingly, the offering price should not be considered an indication of the actual value of the securities. Unless and until our
Common Stock is listed on a national securities exchange or quoted on OTCQB or OTCQX, our Common Stock and Units comprised of common stock
may be sold only at the fixed price. Notwithstanding our belief that upon the effective date of this registration statement our Common
Stock will satisfy the admission requirements for the OTCQB and our intention to make application for quotation on the OTCQB Market, we
cannot assure you that our Common Stock will be quoted on the OTCQB tier.

<div align='center'>32

CAPITALIZATION</div>

The following table sets forth our cash and cash equivalents and
capitalization as of June 30, 2025:

| ● | on an actual basis; and                                                                                                                  |
| ● | On a pro forma basis                                                                                                                     
 to give effect to the sale by us of 1,562,500 Units at the fixed public offering price of $3.20